CD69

CD69 Molekülinformation

Englischer Name	Early activation antigen CD69	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	0	Target-Alias
Höchste Forschungs- und Entwicklungsphase	Preclinical

Englischer Name	Early activation antigen CD69
Target-Alias
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	0
Höchste Forschungs- und Entwicklungsphase	Preclinical

CD69 Produktliste

Attribut
Protein (1)Antibody (1)
Produktbibliothek
Online (2)
Spezies
Human (1)Mouse (1)
Etikett
His Tag (1)- (1)
Marker
Unconjugated (1)PE Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CD9-H5222	Human	HEK293	Human CD69 / CLEC2C Protein, His Tag				In den Warenkorb legen
FABm022-01	Mouse	Hybridoma	PE-Labeled Monoclonal Anti-Human CD69 Antibody, Mouse IgG1 (3C5B7) (0.03% Proclin)				In den Warenkorb legen

Gesamtmenge2

CD69 Molekülhintergrund

Early activation antigen CD69 is also known as C-type lectin domain family 2 member C (CLEC2C), Activation inducer molecule (AIM), Early T-cell activation antigen p60, Leukocyte surface antigen Leu-23. CD69 contains one C-type lectin domain. CD69 / CLEC2C is expressed on the surface of activated T-cells, B-cells, natural killer cells, neutrophils, eosinophils, epidermal Langerhans cells and platelets. CD69 is induced by antigens, mitogens or activators of PKC on the surface of T and B-lymphocytes and by interaction of IL-2 with the p75 IL-2R on the surface of NK cells. CD69 / CLEC2C involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.